Do we know the true mechanism of action of the DPP-4 inhibitors?

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Do we know the true mechanism of action of the DPP-4 inhibitors? / Andersen, Emilie S.; Deacon, Carolyn F.; Holst, Jens Juul.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 1, 2018, p. 34-41.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Andersen, ES, Deacon, CF & Holst, JJ 2018, 'Do we know the true mechanism of action of the DPP-4 inhibitors?', Diabetes, Obesity and Metabolism, vol. 20, no. 1, pp. 34-41. https://doi.org/10.1111/dom.13018

APA

Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018). Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes, Obesity and Metabolism, 20(1), 34-41. https://doi.org/10.1111/dom.13018

Vancouver

Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes, Obesity and Metabolism. 2018;20(1):34-41. https://doi.org/10.1111/dom.13018

Author

Andersen, Emilie S. ; Deacon, Carolyn F. ; Holst, Jens Juul. / Do we know the true mechanism of action of the DPP-4 inhibitors?. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20, No. 1. pp. 34-41.

Bibtex

@article{25b0b5d70b874b31b14373f835804e89,
title = "Do we know the true mechanism of action of the DPP-4 inhibitors?",
abstract = "The prevalence of type 2 diabetes is increasing, which is alarming because of its serious complications. Anti-diabetic treatment aims to control glucose homeostasis as tightly as possible in order to reduce these complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a recent addition to the anti-diabetic treatment modalities, and have become widely accepted because of their good efficacy, their benign side-effect profile and their low hypoglycaemia risk. The actions of DPP-4 inhibitors are not direct, but rather are mediated indirectly through preservation of the substrates they protect from degradation. The two incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are known substrates, but other incretin-independent mechanisms may also be involved. It seems likely therefore that the mechanisms of action of DPP-4 inhibitors are more complex than originally thought, and may involve several substrates and encompass local paracrine, systemic endocrine and neural pathways, which are discussed here.",
keywords = "dipeptidyl peptidase-4 inhibitors, incretin therapy, type 2 diabetes",
author = "Andersen, {Emilie S.} and Deacon, {Carolyn F.} and Holst, {Jens Juul}",
year = "2018",
doi = "10.1111/dom.13018",
language = "English",
volume = "20",
pages = "34--41",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Do we know the true mechanism of action of the DPP-4 inhibitors?

AU - Andersen, Emilie S.

AU - Deacon, Carolyn F.

AU - Holst, Jens Juul

PY - 2018

Y1 - 2018

N2 - The prevalence of type 2 diabetes is increasing, which is alarming because of its serious complications. Anti-diabetic treatment aims to control glucose homeostasis as tightly as possible in order to reduce these complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a recent addition to the anti-diabetic treatment modalities, and have become widely accepted because of their good efficacy, their benign side-effect profile and their low hypoglycaemia risk. The actions of DPP-4 inhibitors are not direct, but rather are mediated indirectly through preservation of the substrates they protect from degradation. The two incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are known substrates, but other incretin-independent mechanisms may also be involved. It seems likely therefore that the mechanisms of action of DPP-4 inhibitors are more complex than originally thought, and may involve several substrates and encompass local paracrine, systemic endocrine and neural pathways, which are discussed here.

AB - The prevalence of type 2 diabetes is increasing, which is alarming because of its serious complications. Anti-diabetic treatment aims to control glucose homeostasis as tightly as possible in order to reduce these complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a recent addition to the anti-diabetic treatment modalities, and have become widely accepted because of their good efficacy, their benign side-effect profile and their low hypoglycaemia risk. The actions of DPP-4 inhibitors are not direct, but rather are mediated indirectly through preservation of the substrates they protect from degradation. The two incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are known substrates, but other incretin-independent mechanisms may also be involved. It seems likely therefore that the mechanisms of action of DPP-4 inhibitors are more complex than originally thought, and may involve several substrates and encompass local paracrine, systemic endocrine and neural pathways, which are discussed here.

KW - dipeptidyl peptidase-4 inhibitors

KW - incretin therapy

KW - type 2 diabetes

U2 - 10.1111/dom.13018

DO - 10.1111/dom.13018

M3 - Journal article

VL - 20

SP - 34

EP - 41

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 1

ER -

ID: 195511468